Home / Business and Economy / AbbVie Buys Apogee Therapeutics for $10.9B
AbbVie Buys Apogee Therapeutics for $10.9B
22 Jun
Summary
- AbbVie agreed to acquire Apogee Therapeutics for $10.9 billion.
- The deal grants AbbVie access to Apogee's lead drug candidate zumilubimab.
- Zumilubimab targets inflammatory diseases like atopic dermatitis and asthma.
AbbVie has entered into an agreement to acquire Apogee Therapeutics for $10.9 billion in an all-cash transaction. The deal is designed to significantly enhance AbbVie's portfolio of immunology treatments.
This acquisition will grant AbbVie control over Apogee's key drug candidate, zumilubimab. This experimental therapy is targeted at a range of inflammatory diseases.
Notably, zumilubimab is being investigated for its potential to treat moderate-to-severe atopic dermatitis and asthma. The acquisition aims to strengthen AbbVie's position in the immunology sector.
Disclaimer: This story has been auto-aggregated and auto-summarised by a computer program. This story has not been edited or created by the Feedzop team.
